Moderna, the US biotech company best known for its COVID‑19 vaccine, hasreportedlybegun early research into a vaccine for hantavirus. The announcement, which drove the company's share price up significantly, has raised questions about what this vaccine might mean for public health and how soon it might be available.
TheBoston Globereported that investors reacted strongly when word circulated that Moderna is working on a hantavirus jab, underscoring how swiftly news of vaccine development can influence biotech stocks. The project is in its earliest stages, and clinical development typically takes years before resulting in a viable, widely available vaccine.
Moderna's shares jumped in trading after reports surfaced that the company has initiated work on a hantavirus vaccine. ASeeking Alphareport noted that news of the early-phase development caused a notable rise in its stock price on the Friday trading session, reflecting investor optimism around emerging infectious disease defences.
A post shared by Aaron Parnas (@aaronparnas)
A World Health Organizationfact sheetnotes that hantaviruses are a group of viruses carried by rodents that can cause serious disease in humans. In the Americas,hantavirus infectioncan lead to hantavirus cardiopulmonary syndrome, a severe respiratory condition with high fatality rates, while in Europe and Asia infections often result in haemorrhagic fever with renal syndrome. There is currently no approved vaccine for hantavirus disease.
Transmission to humans generally occurs through contact with infected rodent excreta. Despite being relatively uncommon, the severity of illness when cases do occur has made vaccines against hantaviruses a long‑standing goal in infectious disease research.
Moderna's reported interest in hantavirus vaccines appears to coincide with a rise in public awareness after acluster of cases linked to cruise ship travelwas reported by the World Health Organization, including confirmed infections and several deaths, managed through international health responses.
While Moderna has not shared extensive public details, the Boston Globereportsthat the company is conducting early vaccine research in collaboration with the US Army Medical Research Institute of Infectious Diseases and with Korea University's Vaccine Innovation Center. These partnerships aim to explore the potential for mRNA vaccine technology to generate immune responses against hantaviruses.
Moderna's broader research strategy includes work on vaccines for multiple emerging diseases, leveraging its mRNA platform that proved successful in the COVID‑19 pandemic. This technology could potentially enable faster responses to new threats than traditional vaccine methods.
Despite sporadic outbreaks, hantavirus has not historically received the same level of sustained funding as some other infectious diseases.Outbreaksoften occur in geographically limited areas and disproportionately affect poorer regions, which can challenge commercial incentives for vaccine development.
Source: International Business Times UK
